Jump to content [AK + s] Jump to navigation [AK + 3]

Q3 Report 2015

English | Dutch
  • Twitter
  • LinkedIn

Primary Menu

  • The Galapagos Group
    • Letter from management
    • At a glance
    • Risk factors
    • The Galapagos share
    • Disclaimer and other information
  • Financial statements
    • Consolidated statements of income and comprehensive income
    • Consolidated statements of financial position
    • Consolidated cash flow statements
    • Consolidated statements of changes in equity
  • Notes
    • Basis of preparation
    • Significant accounting policies
    • Details of the unaudited Q3 2015 results
    • Contingencies and commitments
    • Events after the end of the reporting period
    • Approval of interim financial statements
  • Report of the Auditor
    • Report of the Auditor

The Galapagos Group

  • Letter from management
  • At a glance
  • Risk factors
  • The Galapagos share
  • Disclaimer and other information

You are here:

  • Home
  • The Galapagos Group
  • The Galapagos share
The Galapagos share

The Galapagos share

Performance of the Galapagos share on Euronext

Performance of the Galapagos share on Euronext (line_chart)Performance of the Galapagos share on Euronext (line_chart)

previous pagenext page
  • Twitter
  • LinkedIn

Related links

  • Details of the unaudited Q3 2015 results
Download Center

We look forward to bringing filgotinib into Phase 3, preferably together with a strong pharma partner to ensure the fastest route to the market.

Onno van de Stolpe, CEO
to page top

Service

  • Glossary of terms
  • Downloads
  • Financial calendar
  • Galapagos Corporate Website

Last Update 12 November 2015

Galapagos Q3 Report 2015 (PDF)

Download the entire report as PDF.

Download PDF (1.7 MB)
English | Dutch
  • © Copyright 2015 Galapagos NV
  • Colophon
  • Contact
  • Sitemap
© Copyright 2015 Galapagos NV
nexxar - digital reporting evolved - Online Report